New Risk • Apr 04
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$6.4m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.4m free cash flow). Earnings have declined by 11% per year over the past 5 years. Shareholders have been substantially diluted in the past year (413% increase in shares outstanding). Revenue is less than US$1m (US$299k revenue). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Market cap is less than US$100m (US$40.6m market cap). Announcement • Nov 10
TAO Synergies Inc., Annual General Meeting, Dec 18, 2025 TAO Synergies Inc., Annual General Meeting, Dec 18, 2025. Announcement • Oct 25
TAO Synergies Inc. announced that it has received $11 million in funding On October 24, 2025, TAO Synergies Inc. closed the transaction. The company raised the funding pursuant to Regulation D in the transaction from 7 investors. Announcement • Oct 14
TAO Synergies Inc. announced that it expects to receive $11 million in funding TAO Synergies Inc. announced that it has entered into securities purchase agreement with certain accredited investor to issue 11,000 series E convertible preferred stock at an issue price of $1,000 per share and warrants to purchase up to an aggregate of 1,375,000 shares of common stock for gross proceeds of $11,000,000 on October 13, 2025. The transaction includes participation from existing investor, James Altucher and a new investor, DCG. The conversion price is of $8 and will be convertible into 1,375,000 share. The holders of the preferred stock will be entitled to dividends of 7% per annum. The warrants are exercisable immediately at an exercise price of $8 per share and expire five years from the date of issuance. The transaction is expected to close on or about October 15, 2025, subject to the satisfaction of customary closing conditions. The private placement is exempt from the registration requirements of the securities act of 1933, as amended pursuant to the exemption for transactions by an issuer not involving any public offering under section 4(a)(2) of the securities act and rule 506 of Regulation D of the securities act and in reliance on similar exemptions under applicable state laws. Announcement • Sep 23
TAO Synergies Inc. Launches The Tao Daily, Premier Media Platform for All Things Bittensor TAO Synergies Inc. announced the launch of "The Tao Daily," a comprehensive media, news, and insight platform dedicated to Bittensor (TAO) and the TAO ecosystem. The TAO Daily is designed not only to be up to date on all news related to TAO, but also to educate the market about the Bittensor ecosystem, its native token TAO, and the specialized subnets within the TAO network. The new media platform highlights Bittensor ecosystem developments and provides transparency into the rapidly growing world of decentralized AI as well as resources useful to TAO users and investors. Created by James Altucher, leader of TAO Synergies'digital asset treasury strategy, The TAO Daily aims to be the single authoritative source for all Bittensor-related information. The content platform features daily news, interactions with subnet leaders and ecosystem contributors, videos and podcasts, and tutorials for developers. It also offers valuable insights for TAO investors and adopters including tokenomics and staking opportunities. Announcement • Jun 24
Synaptogenix, Inc. announced that it has received $5.5 million in funding On June 23, 2025, Synaptogenix, Inc. closed the transaction. The company has raised $5,500,000 from 5 investors pursuant to Regulation D. The company paid $385,000 as sales commission. Announcement • Jun 10
Synaptogenix, Inc. announced that it expects to receive $5.5 million in funding Synaptogenix, Inc. announced that it has entered into a securities purchase agreement to issue an aggregate of 5,500 shares of the company’s newly designated series D convertible preferred stock at a price of $1,000 per share and warrants for the gross proceeds of $5,500,000 on June 9, 2025. The warrants will be exercisable up to an aggregate of 1,833,333 shares and series D shares will be convertible at a conversion price of $3 per share. The closing of the private placement is expected to occur on June 10, 2025, subject to the satisfaction of customary closing conditions. New Risk • Jun 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 16% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (US$3.35m market cap). Minor Risk Share price has been volatile over the past 3 months (16% average weekly change). Announcement • Oct 29
Synaptogenix, Inc., Annual General Meeting, Dec 06, 2024 Synaptogenix, Inc., Annual General Meeting, Dec 06, 2024. Board Change • Oct 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 1 highly experienced director. Chairman of the Scientific Advisory Board George Perry was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • Sep 24
Synaptogenix, Inc. announced that it has received $3.207 million in funding On September 23, 2024, Synaptogenix, Inc. closed the transaction. The transaction included participation from four investors. Announcement • Sep 12
Synaptogenix, Inc. announced a financing transaction Synaptogenix, Inc. announced a private placement of 3,207 shares of the company’s preferred stock and warrants on September 11, 2024. The warrants will be exercisable into shares at a price of $4 per share. The transaction is now expected to close on September 12, 2024. New Risk • Jul 11
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 27% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 27% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (319% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$5.29m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$24m net loss in 3 years). Announcement • Jun 26
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis Synaptogenix, Inc. announced that the Food & Drug Administration (FDA) has authorized an Investigational New Drug (IND) application for Bryostatin-1 as a potential treatment for multiple sclerosis (MS). The fully-funded, open-label clinical trial will be held and managed at Cleveland Clinic Neurological Institute's Mellen Center for Multiple Sclerosis. The study will utilize state-of-the-art 7-tesla (7T) magnetic resonance imaging (MRI) technology to identify biomarkers for evaluating Bryostatin-1's impact on the brain. Bryostatin-1 is a small molecule that works by activating protein kinase C (PKC) enzymes required for maintaining synapse health and is involved in learning and memory. The therapy may also enhance anti-inflammatory efficacy to prevent degradation of the insulating sheath around nerve fibers. Announcement • Apr 27
Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing Synaptogenix, Inc. announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on April 22, 2024, informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a) (2) ("Listing Rule") for continued listing on The Nasdaq Capital Market. On April 24, 2023, Synaptogenix received notice from the Listing Qualifications Department of Nasdaq indicating that the Company was not in compliance with the Listing Rule, as its common stock had failed to meet a closing bid price of $1.00 or more for 30 consecutive business days. In order to regain compliance with the Listing Rule, the Company's common stock was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days. The Company conducted a 1-for-25 reverse split of its common stock on April 4, 2024, with the goal of increasing the trading price of the common stock. The common stock began trading on a split-adjusted basis on April 5, 2024, under the new CUSIP number 87167T 300. Announcement • Apr 11
Synaptogenix, Inc. (NasdaqCM:SNPX) acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd. Synaptogenix, Inc. (NasdaqCM:SNPX) acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd. on April 9, 2024. Synaptogenix Chairman Josh Silverman and Director Bruce Bernstein to join PsygaBio's board of directors. These board members remain in their roles at Synaptogenix as the Company continues its work on Bryostatin for therapeutic treatment of neurodegenerative disorders.
Synaptogenix, Inc. (NasdaqCM:SNPX) completed the acquisition of Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd. on April 9, 2024. New Risk • Feb 22
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (181% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$4.14m market cap). Announcement • Nov 14
Synaptogenix, Inc., Annual General Meeting, Dec 20, 2023 Synaptogenix, Inc., Annual General Meeting, Dec 20, 2023, at 11:00 US Eastern Standard Time. Agenda: To elect two directors to serve three-year terms expiring in 2026; to approve a proposed amendment to the Synaptogenix, Inc. articles of incorporation, as amended to effect a reverse stock split of common stock at a ratio between 1-for-8 and 1-for-25; to approve a proposed amendment to the Synaptogenix, Inc. 2020 Equity Incentive Plan to, among other things, increase the number of shares available for the grant of awards by 3,000,000 shares; to ratify the appointment of Morison Cogen LLP as company independent registered public accounting firm for the fiscal year ending December 31, 2023; and to transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof. New Risk • Nov 06
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 183% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (183% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$5.84m market cap). New Risk • Jul 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (US$7.65m market cap). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (8.1% increase in shares outstanding). Announcement • Dec 17
Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease Synaptogenix, Inc. announced topline data from its National Institute of Health (NIH)-sponsored Phase 2 clinical trial of Bryostatin-1 for the treatment of advanced Alzheimer's disease. The trial's primary endpoint of change from baseline in the Severe Impairment Battery (SIB) total score assessment obtained after completion of the second course of treatment (week 28) was not met with statistical significance. An average increase in the SIB total score of 1.4 points and 0.6 points was observed for the Bryostatin-1 and placebo groups, respectively, at week 28. The Phase 2 clinical trial was a randomized, double-blind, placebo-controlled study comparing bryostatin-1 to placebo for long-term efficacy in the treatment of advanced and moderately severe AD in the absence of memantine. The study was conducted with financial support from the National Institute on Aging (NIA) and the National Cancer Institute (NCI), both part of the National Institutes of Health (NIH). About SynaptogenixSynaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated Bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. Announcement • Nov 23
Synaptogenix, Inc. announced that it has received $15 million in funding On November 21, 2022, Synaptogenix, Inc. closed the transaction. Announcement • Nov 19
Synaptogenix, Inc. announced that it expects to receive $15 million in funding Synaptogenix, Inc. announced that it has entered into a security purchase agreement for the issuance of 15,000 Series B convertible preferred stock at a price of $1,000 per convertible preferred stock for gross proceeds of $15,000,000 on November 17, 2022. The transaction will include participation from returning accredited investors. The convertible preferred stock initially convertible into up to 1,935,485 shares of the company's common stock, par value $0.0001 per share at a conversion price of $7.75 per share. The company has also issued warrants to acquire up to an aggregate of 1,935,485 shares of common stock. The company will be required to redeem the preferred shares in 15 equal monthly installments, commencing on April 1, 2023. The holders of the preferred shares will be entitled to dividends of 7% per annum. The transaction is exempt from the registration requirements of the Securities Act pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act of 1933, and Rule 506 of Regulation D of the Securities Act. The closing of the transaction is expected to occur on November 21, 2022. Announcement • Aug 26
Synaptogenix, Inc., Annual General Meeting, Oct 11, 2022 Synaptogenix, Inc., Annual General Meeting, Oct 11, 2022, at 11:00 US Eastern Standard Time. Agenda: To elect two directors to serve three-year terms expiring in 2025; to approve a proposed amendment to the Synaptogenix, Inc. 2020 Equity Incentive Plan to increase the number of shares available for the grant of awards by 750,000 shares; to ratify the appointment of Morison Cogen LLP as company's independent registered public accounting firm for the fiscal year ending December 31, 2022; and to transact such other business that is properly presented at the annual meeting and any adjournments or postponements thereof. Announcement • Jul 21
Synaptogenix, Inc. Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data Synaptogenix Inc. announced, in preparation for its next phase of Bryostatin clinical development, the dosing of its first patient in the Company's open-label dose optimization clinical trial. Synaptogenix's therapeutic lead drug to treat Alzheimer's disease (AD), Bryostatin, recently showed a statistically significant improvement in the treatment group that was not observed in the placebo group in two pilot, placebo-controlled Phase 2 trials. (Thompson et al., JAD 2022). In the current 6-month trial, enrollment is complete and clinical testing is proceeding toward conclusion. The Company expects to announce topline data from its National Institutes of Health ("NIH") - sponsored, Phase 2b clinical trial of Bryostatin-1 for patients suffering from advanced and moderately severe AD during the fourth quarter of 2022. Announcement • Apr 20
Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial Synaptogenix, Inc. announced that it has completed enrolling its target of 100 patients for its ongoing National Institutes of Health ("NIH") sponsored Phase 2b clinical trial of Bryostatin-1 for patients suffering from advanced and moderately severe Alzheimer's disease ("AD"). The company expects to announce topline data from the study during the fourth quarter of 2022. Synaptogenix also reports that the independent Data Safety Monitoring Board ("DSMB") overseeing the trial has confirmed the absence of any drug-related adverse safety issues. Bryostatin-1 caused highly significant cognitive enhancement (4.0 SIB psychometric score above baseline) for the pre-specified patients who received Bryostatin-1 in the absence of Namenda in the company's two previous, consolidated 3-month pilot trials, recently published in a peer-reviewed article (JAD, 2022) – while the Placebo-treated patients showed no significant benefit. Bryostatin-1 treatment has now been extended to include double the number of doses (N = 14) in the current 6-month, placebo-controlled trial, in which randomized enrollment has been carefully controlled for balanced baselines in the treatment and placebo cohorts. Patients will have been observed for as long as three months after all dosing cessation, given the persistence of benefit for at least 30 days after dosing that was previously observed. Announcement • Jul 15
Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline Synaptogenix, Inc. announced that its abstract has been accepted at the Alzheimer's Association International Conference ("AAIC"), which will be held online and in-person July 26-30, 2021. The Company's lead drug candidate, Bryostatin-1, will be featured in a poster presentation entitled: "Bryostatin Restores Cognitive Functions Above Baseline in Advanced Alzheimer's Disease ("AD") Patients: A Regenerative Therapeutic Strategy." Bryostatin improved cognition in patients with advanced Alzheimer's disease significantly above their baseline levels in recently completed data analyses that consolidated all pre-specified patients under identical protocol conditions in the two Phase 2 pilot trials. The company believes the results provide evidence of significant AD patient cognitive improvement – with potential clinically meaningful benefit – at a level not observed with the randomized placebo control patients. Announcement • Jun 30
Synaptogenix, Inc. announced that it has received $12.477342 million in funding On June 29, 2021, Synaptogenix, Inc. closed the transaction. The company raised $12,477,342 in the transaction from 14 investors pursuant to Regulation D. Recent Insider Transactions • Jun 17
President recently bought US$83k worth of stock On the 14th of June, Daniel Alkon bought around 10k shares on-market at roughly US$8.26 per share. This was the largest purchase by an insider in the last 3 months. This was Daniel's only on-market trade for the last 12 months. Announcement • Jun 16
Synaptogenix, Inc. announced that it expects to receive $12.499998 million in funding Synaptogenix, Inc. (NasdaqCM:SNPX) announced that it has entered into a securities purchase agreement for a private placement of 1,656,287 units at a price of $7.547 for gross proceeds of approximately $12,499,998 on June 14, 2021. The transaction was led by existing institutional shareholders. Each unit consists of one share of common stock and one warrant. Each warrant is exercisable for five years at a price of $8.51 per share of common stock. The transaction is expected to close on or about June 16, 2021, subject to customary closing conditions. Announcement • Jun 10
Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update Synaptogenix, Inc. announced an update on its ongoing National Institutes of Health ("NIH") sponsored Phase 2b clinical trial of Bryostatin-1 in patients suffering from moderately severe Alzheimer's disease ("AD"). To date, the Company has now dosed 58 of its target 100 patients. Seventeen sites continue to be live. Additionally, the independent Data Safety Monitoring Board ("DSMB") overseeing the trial convened to assess the safety of Bryostatin through an interim analysis and confirmed that 40 advanced AD patients have been dosed with Bryostatin without any significant safety issues. Announcement • Feb 14
Synaptogenix, Inc. announced that it has received $14.0033 million in funding On February 12, 2021, Synaptogenix, Inc. (OTCPK:SNPX) closed the transaction. Announcement • Feb 05
Synaptogenix Announces Licensing Agreement with Stanford University; and Supply Agreement with Bryologyx, Inc Synaptogenix Inc. announced that it has received its first batch of synthetic Bryostatin. The Company has an exclusive licensing agreement with Stanford University for synthetic Bryostatin for all neurologic indications, as well as a supply agreement in place with Bryologyx Inc. as previously announced. To date, Synaptogenix has relied upon supply of Bryostatin, derived from natural sources, from the National Cancer Institute of Health. Announcement • Jan 22
Synaptogenix announced that it expects to receive $14 million in funding Synaptogenix (OTCPK:SNPX) announced that it has entered into a definitive securities purchase agreement for a private placement led by new and existing investors for gross proceeds of approximately $14 million on January 21, 2021. The transaction will include participation from accredited investors. The company will issue common stock at a purchase price of $1.5 per share, one-year warrants to purchase an equal number of the company's shares of common stock at an exercise price of $2.1275 and five-year warrants to purchase an equal number of the company's shares of common stock at an exercise price of $1.725 per share in the transaction. The closing of the transaction is subject to the satisfaction of customary closing conditions. Announcement • Dec 12
Synaptogenix Inc Announces CEO Changes On December 1, 2020, Neurotrope Inc. ("Neurotrope"), Petros Pharmaceuticals Inc.("Petros"), PM Merger Sub 1, LLC, a Delaware limited liability company and a wholly-owned subsidiary of Petros ("Merger Sub 1"), PN Merger Sub 2 Inc., a Delaware corporation and a wholly-owned subsidiary of Petros ("Merger Sub 2"), and Metuchen Pharmaceuticals LLC, a Delaware limited liability company ("Metuchen"), consummated the transactions (the "Mergers") contemplated by that certain Agreement and Plan of Merger by and among the Company, Petros, Merger Sub 1, Merger Sub 2 and Metuchen, dated as of May 17, 2020, as amended by the First Amendment to the Original Merger Agreement (the "First Amendment"), dated as of July 23, 2020 and the Second Amendment to the Original Merger Agreement, dated as of September 30, 2020. On December 1, 2020 (the "Separation Date"), Charles S. Ryan, J.D., Ph.D. was terminated from his employment with Neurotrope and Synaptogenix, including his positions as the Chief Executive Officer of Neurotrope and any and all other positions that Dr. Ryan held with Neurotrope, Synaptogenix, or any of Neurotrope's subsidiaries or other affiliated entities. On December 7, 2020, the Company entered into an offer letter (the "Offer Letter") with Alan J. Tuchman, M.D., pursuant to which Dr. Tuchman agreed to serve as the Company's Chief Executive Officer, commencing on December 7, 2020 (the "Start Date").